BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase II Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

BioRestorative Therapies, Inc. announced that the first patient has been enrolled in the company’s Phase II clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease.